New Liquid Biopsy shows promise for early pancreatic Cancer Detection
A new research study published in Nature Medicine has reported promising findings for a blood based liquid biopsy that could help detect pancreatic ductal adenocarcinoma at an early stage. The study explores a new approach that may improve the detection of pancreatic cancer before the disease becomes advanced.
Pancreatic ductal adenocarcinoma, commonly known as PDAC, is the most common form of pancreatic cancer. Detecting the disease early remains difficult because pancreatic cancer can develop with few or nonspecific symptoms in its initial stages. Many patients are therefore diagnosed after the cancer has already progressed.
Researchers conducted an international multicenter study involving 1,785 individuals from four countries. The team examined blood samples to identify molecular signals associated with pancreatic ductal adenocarcinoma.
The researchers developed a panel containing 10 microRNAs. MicroRNAs are small molecules that help regulate gene activity and can be detected in blood. The study investigated whether changes in these molecules could provide a signal of early pancreatic cancer.
The researchers then developed a composite biomarker called PANXEON. The test combines the microRNA signature with carbohydrate antigen 19-9, commonly known as CA19-9. CA19-9 is an established biomarker used in pancreatic cancer management, although it has limitations and is not considered sufficient for general population screening.
According to the study, the microRNA signature achieved an area under the curve of 88.6 percent in the testing cohort and detected early stage pancreatic ductal adenocarcinoma with a sensitivity of 83.8 percent. When combined with CA19-9, the reported sensitivity for stage I and stage II pancreatic cancer increased to 86.8 percent.
The researchers also examined whether the biomarker could provide information about treatment response and recurrence. In a smaller group of 19 patients, microRNA levels decreased during chemotherapy administered before surgery and following surgery. The researchers also observed increases in the biomarker before disease recurrence.
The study further evaluated patients with high risk pancreatic cysts. PANXEON detected high grade dysplasia in 64.3 percent of these individuals, indicating potential applications beyond detecting established pancreatic cancer.
Despite the encouraging findings, the liquid biopsy is not yet an established screening test for pancreatic cancer. Further large prospective studies will be necessary to validate the results and determine how the approach could be incorporated into clinical practice.
The findings highlight the growing potential of liquid biopsy and microRNA biomarkers in the search for more effective methods of early pancreatic cancer detection. Earlier identification could eventually help doctors investigate suspicious cases sooner and improve opportunities for timely treatment.
Reference: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma
Aging is not the same for everyone, new Science study finds
A new study published in Science is offering a closer look at what happens inside the body as people age, revealing that changes in gene activity and metabolism can follow complex and highly individual patterns.
The study, titled “Longitudinal dynamics of gene expression and metabolomics in an aging population cohort,” examines how molecular changes unfold over time by combining gene-expression analysis and metabolomics the study of small molecules produced during metabolism.
Unlike research that compares different people at different ages, the longitudinal approach allows scientists to track molecular changes within the same individuals over an extended period. This provides a more detailed picture of biological aging and how it may differ from chronological age.
Aging leaves a molecular fingerprint
Researchers identified thousands of age-associated changes involving genes and metabolites. These molecular shifts were linked to biological processes involved in areas such as immune function, metabolism and age-related health. One of the important implications of the research is that people of the same chronological age may not experience identical biological changes. In other words, turning 60, 70 or 80 does not necessarily mean that every person's body is undergoing the same molecular transformation. The findings highlight why researchers are increasingly interested in measuring biological age and individual aging trajectories rather than relying solely on the number of years a person has lived.
Environment and body rhythms may also matter
The research also points to factors beyond chronological age that can influence molecular patterns. Genetic differences, circadian rhythms and seasonal variation were among the factors associated with changes in gene expression and metabolites.
This adds to growing evidence that aging is influenced by a combination of genetics, lifestyle, environment and biological rhythms rather than being controlled by age alone.
Could this improve healthy aging?
The researchers' findings could have implications for future precision medicine and healthy-aging research. Long-term monitoring of molecular changes may eventually help scientists understand why some people remain healthy into old age while others develop age-related diseases earlier. However, the study does not mean that scientists can currently use gene-expression or metabolite measurements to accurately predict an individual's lifespan or determine exactly how fast they are aging. More research involving larger and more diverse populations will be needed.
Reference: Longitudinal dynamics of gene expression and metabolomics in an aging population cohort
Gene Therapy Reverses Heart Damage in Landmark Cardiomyopathy Study
ALPK3 gene therapy has shown promising results in restoring heart function in mouse models and laboratory-grown human heart tissue, according to a new study published in Nature Cardiovascular Research. Researchers developed an adeno-associated virus (AAV) gene therapy to deliver a functional copy of the ALPK3 gene, mutations in which can cause inherited cardiomyopathy and serious heart muscle disease.
In mice with established cardiomyopathy, ALPK3 gene therapy reversed cardiac abnormalities and restored aspects of heart function. Researchers also found that more than 95% of the molecular disease signature associated with the condition was reversed after treatment. The team then tested the approach in human cardiac organoids. The therapy restored contractile function in models carrying disease-causing ALPK3 mutations.
Interestingly, the treatment also improved heart contraction in human cardiac organoids carrying TTN truncating mutations. TTN is a major gene associated with dilated cardiomyopathy. The findings raise the possibility that ALPK3 gene therapy could eventually provide a new treatment strategy for multiple forms of genetic heart disease.
However, the research remains preclinical. The therapy has not yet been tested in human patients, and further studies are needed to assess its safety, effectiveness and potential for clinical trials.